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Summary 
 
 1α,25-Dihydroxyvitamin D3 (1,25(OH)2D3) has many biologically useful effects beyond 
calcium regulation, and many kinds of new vitamin D derivatives have been synthesized and 
tried in clinical applications. However, the mode of action of the strength of each analogue has 
not yet been made clear. 
I investigated the nuclear receptor binding in the 1α,25-dihydroxy-22-oxavitamin D3 (OCT) 
and 1α-hydroxyvitamin D3 (ALF) target cells by using Microautoradiography (MicroARG) for 
this study. 
As a result, the nuclear receptor binding of 3H-OCT appeared equal to or higher than that of 
3H-1,25(OH)2D3 in the parathyroid chief cells despite their low blood concentration (Chapter1). 
In addition, the parathyroid chief cells required the lowest relative receptor saturation dose from 
among the other target cells that regulate calcium homeostasis (Chapter 2). In addition, the 
possibility of expanding the application of OCT was suggested for selective localization in 
pancreatic tumors (Chapter 3) and in sweat glands (Chapter 4). In addition, by using combined 
radioassay, it was suggested that 1α(OH)D3 continuously supplies osteoblasts with a converted 
1α,25(OH) 2D3 (Chapter 5).   
The important findings concerning the mode of action for OCT and ALF could be obtained by 
using the improved MicroARG. This method is considered to be a valuable tool in future drug 
development. 
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General Introduction 
 
1α,25-Dihydroxyvitamin D3 (1,25(OH)2D3) has many biologically useful effects beyond 
calcium regulation, such as suppression of parathyroid hormone (PTH) synthesis and secretion, 
regulation of cell differentiation and inhibition of cell proliferation in mice and human myeloid 
cells, etc. However, the clinical use of 1,25(OH)2D3 is limited due to the side effects caused by 
hypercalcemia. The importance of vitamin D derivatives used as pharmaceuticals has increased 
with the improved technology surrounding chemical synthesis, and many kinds of new vitamin 
D derivatives have been synthesized and tried in clinical applications for diseases such as 
osteoporosis, psoriasis, and secondary hyperparathyroidism (Table 1). However, the mode of 
action of the strength of each analogue has not yet been made clear. 
1α,25-Dihydroxy-22-oxavitamin D3 (OCT) is a synthetic analogue of 1,25(OH)2D3 that retains 
many of the therapeutically useful properties of 1,25(OH)2D3, but has less calcemic activity 
compared to 1,25(OH)2D3. The low calcemic activity of OCT is taken into consideration 
because of the differences in biological activity, such as the binding potencies to 1,25(OH)2D3 
receptor (VDR) and the serum vitamin D binding protein (DBP). OCT has been suggested to 
have therapeutic potential for secondary hyperparathyroidism since it was proven to suppress 
PTH secretion and gene expression in vivo. However, it was unclear whether the therapeutic 
effect is sustainable despite low blood levels and whether OCT is selectively distributed to the 
parathyroid gland as the target cells. In this case, however, it was impossible to isolate only the 
parathyroid excluded from the thyroid tissue in mice and rats due to the tissue size. The in vivo 
cellular and sub-cellular localizations must be demonstrated to clarify the selective localization 
of OCT to the parathyroid but not to the thyroid, because it was impossible to clarify it due to 
the MacroARG resolution. (Table 2). Therefore, I predict that the Microautoradiography 
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(MicroARG) technique will be a useful tool for studying the mode of action of vitamin D 
analogs.    
 
MicroARG has been used since the 1970’s to clarify the distribution of important radiolabeled 
molecules like hormones at the microscopic level. In particular, the thaw-mount method 
developed by Dr. W. E. Stumpf is indispensable for detecting diffusible compounds like steroids, 
such as estradiol and 1,25(OH)2D3, which may be easily lost from the initial tissue or 
redistributed to another. At first, I started a study on whether this technique could be used. 
Although MicroARG is highly sensitive and has a high resolution, there were very few reports 
on its use in the drug development process. There may be two reasons for this. One is the 
chemical technology for the synthesis of vitamin D derivatives and another is the techniques 
used for MicroARG. Recent technological advances have made a variety of synthetic derivatives 
possible. On the other hand, although the principle is very simple, the technical aspects require 
specific skills and optimization. The method is shown in Figure 1. 
It was found through a variety of trials and errors that the frozen section conditions were the 
most important factors. Pathologically beautiful specimens were successfully prepared without 
artifacts using the following optimization.   
 False positive artifacts occur frequently in otherwise uniform thin thicknesses and/or due to 
damaged or wrinkled frozen sections. In addition, the conditions of thaw-mount adhesive 
pressure and photographic development also affect the results. The thickness of the frozen 
section was adjusted to 4-µm by using a cryostat set to minus 25 degrees or less, because a 
thickness of more than 5 µm induced artifacts. A quality check of the frozen sections was 
conducted using standard slides confirmed to be a micrometer thick under a proof light in a dark 
room. Regarding the artifact based on the pressure, no-artifact was ensured by checking the 
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zero-day development of a specimen.     
 A false negative artifact was induced in a high humidity environment, especially in an open 
black box cooled in a refrigerator. Then, the specimen was kept for more than 2 hours in a 
strictly controlled room at 20 degrees and 20% humidity. In addition, the sections from the same 
sample were divided into different boxes to avoid any accidents from happening.       
 According to a careful autoradiography, the localization of OCT in the target cells was detected 
at a high sensitivity and high resolution level that may not be obtainable from using any other 
method. The difference in gained information between MicroARG and MacroARG is presented 
in Fig. 2. MicroARG is essential for cellular and subcellular analysis.       
 In addition, by adding the concept of pharmacokinetics, such as the time course and dose 
combined with qualification using image analysis, MicroARG was applicable for analyzing the 
mode of action for important molecules as a more powerful and useful tool beyond a mere 
analysis of the drug distribution. 
 
 In this study, I investigated the mechanism of 1,25-dihydroxy-22-oxavitamin D3 (OCT) and 
1α-hydroxyvitamin D3 (ALF) by using MicroARG. As a result, it was suggested that OCT and 
ALF have some useful clinical potential compared with 1,25(OH)2D3. My work presented the 
five following points: (1) the high amount of nuclear uptake of OCT to parathyroid cells 
compared with 1,25(OH)2D3, (2) the parathyroid chief cells required the lowest relative receptor 
saturation dose for OCT from among the duodenum, kidney, and skin, (3) the selective 
distribution of OCT in different tumor cell populations, (4) the selective distribution of OCT in 
sweat gland epithelial and myoepithelial cells, and (5) the sustained osteoblast nuclear receptor 
binding of a converted 1,25(OH)2D3 from ALF. 
 
Common Name Compound Name Abbreviation Development  
Cord 
Trivial  
Name 
Calcitriol 1a,25-Dihydroxy- 
vitamin D3 
1a,25(OH)2D3 Rocaltrol Active form  
vitamin D3 
Cholecalciferol Vitamin D3 
Calciifediol 25-Hydroxy- 
vitamin D3 
25(OH)D3 
Alfacalcidol 1a-Hydroxyvitamin D3 1aOHD3 Alfarol,  
Onealfa 
Prodrug ALF 
Maxacalcitol 1a-,25-Dihydroxy- 
22-oxa-vitamin D3 
Oxarol 22-oxacalcitol OCT 
Eldecalcitol 1a-,25-Dihydroxy- 
2b-(3-hydroxypropoxy)vitamin D3 
ED-71 
Adaptation 
disease 
Osteoporosis 
2nd hyperparathyroidism 
Psoriasis 
Osteoporosis 
(Osteoporosis) 
Calcipotriol 1a-,24-Dihydroxy- 
22-ene-24-cyclopropyl vitamin D3 
MC903 Psoriasis Daivonex 
Tacalcitol (1a,3b,5Z,7E,24R)-isomer 1a, 
24-dihydroxyvitamin D3 
Psoriasis Bonalfa 
Paricalcitol 19-nor-1a,25-Dihydroxy- 
vitamin D2 
2nd hyperparathyroidism Zemplar ABT-358 
Falecalcitriol Fulstan 
Hornel 
1a-,25-Dihydroxy- 
26,27-hexafluorocholecalciferol 
2nd hyperparathyroidism 
Doxercalciferol Hectorol 1a-Hydroxyergocalciferol 2nd hyperparathyroidism 
(Edirol)  
Product 
Name 
Table 1.  Compounds List 
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MacroARG or BAS 
Radioassay 
：homogenate 
Quantification Detection of 
intact compound 
Metabolite Resolution 
Organ level 
 (mm) 
Whole organ 
○ 
◎ 
× 
Including  
metabolite 
× 
◎ ◎ 
Operation  
◎ 
△ 
Sensitivity 
MicroARG 
Cell level 
(300 nm) 
○ 
Grain number 
× 
○ (indirect) 
Competition 
× ◎ 
△ 
△ 
Method 
Table 2.  Methods List 
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Slide grass 
emulsion 
(Thickness:3～4mm) 
Development (1 month～1 year) 
Administration of  radiolabeled compound → Dissection of tissue  
→ Freezing (unfixed, unembedding) 
Frozen section 
Stain 
Image analysis 
Thaw-mount method 
nuclei 
cytoplasm 
Target cell 
Silver grains 
Fig 1.  Procedure of Microautoradiography 
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1 
2 
1 
2 
high affinity & low capacity 
MicroARG can detect the target cells as 
oligodendrocyte in brain, while MacroARG cannot 
do at area 1 and 2. 
MicroARG 
MacroARG 
  (BAS) 
Brain 
MicroARG 
Fig 2.  Resolution of MicroARG and MacroARG 
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CHAPTER 1 
In vivo time-course of receptor binding in the parathyroid gland of the 
vitamin D analogue [3H]1,25-dihydroxy-22-oxavitamin D3 compared with 
[3H]1,25-dihydroxyvitamin D3, determined by micro-autoradiography 
 
Abstract 
 
1,25-Dihydroxy-22-oxavitamin D3 (22-oxacalcitriol, OCT), is a new synthetic analogue of 
1,25-dihydroxy-vitamin D3 (1,25(OH)2D3, calcitriol), to be used in the treatment of secondary 
hyperparathyroidism. This study used receptor micro-autoradiography in the parathyroid gland 
to determine and compare the time-course of receptor binding between OCT and 1,25(OH)2D3. 
Mice were injected with 4 µg/kg of [26-3H]OCT or [26,27-methyl-3H]1,25(OH)2D3, and killed 
at 5, 15, 30 min, 1, 2, 4, 8, 12, and 24 h afterwards. Thyroid-parathyroid tissue was excised and 
autoradiograms were prepared. Under identical conditions of dose and adjusted specific 
radioactivity between [3H]OCT and [3H]1,25(OH)2D3, the plasma concentration of [3H]OCT 
was much lower than that of [3H]1,25(OH)2D3. In the parathyroid at all time points, chief cell 
nuclei were labeled with varying degrees while connective tissue cells remained unlabelled. 
Nuclear receptor binding of [3H]OCT appeared equal to or higher than that of [3H]1,25(OH)2D3. 
Nuclear uptake of [3H]OCT was maximal at 15 min and higher than that of [3H]1,25(OH)2D3, 
which was maximal at 1 h after injection. Low levels of nuclear retention of the two compounds 
were still similarly detectable at 12 h. The results indicate the high affinity of OCT to 
parathyroid cells, and suggest that OCT has a higher therapeutic potential than 1,25(OH)2D3, 
especially under clinical conditions, at which OCT with its lower calcaemic effect would allow 
treatment with a dose several times higher than 1,25(OH)2D3.      
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Introduction 
The study of vitamin D distribution in the body with the sensitive receptor 
micro-autoradiography method has identified over 50 specific target cell populations, many of 
them hitherto unknown (Stumpf et al. 1979a, Stumpf 1995a). Based on that knowledge and 
follow-up studies, a new concept of vitamin D action has evolved. The traditional concept of 
vitamin D as “the calcium homeostatic steroid hormone” (Norman 1979) is too narrow. Vitamin 
D may rather be designated as a polyfunctional hormone for seasonal adaptation of growth, 
reproduction and survival, with cellular actions related to the regulation of proliferation and 
differentiation for growth and repair, and endocrine and exocrine secretion for improvement of 
adaptive functions (Stumpf 1995a). Systemic calcium regulation is only a part of the 
physiologic mechanism of vitamin D action, albeit of toxicologic significance. 
  The numerous target tissues newly discovered by autoradiography using tritium-labelled 
1,25-dihydyoxy-vitamin D3 (1,25(OH)2D3, calcitriol), and its analogue 
1,25-dihydroxy-22-oxavitamin D3 (22-oxacalcitriol, OCT), are regions of the brain and spinal 
cord, heart muscle with elevation of atrial natriuretic peptide, adrenal medulla with effects on 
tyrosine hydroxylase mRNA synthesis, keratinocytes of skin epidermis, hair sheaths and 
sebaceous glands, thymus reticulo-epithelial cells, G-cells in the stomach, pyloric muscle cells, 
neck mucus cells of gastric glands, pituitary cells, especially thyrotropes with elevation of 
thyroid-stimulating hormone, prostate epithelium and muscle cells, ductuli efferentes and caput 
of the epididymis, ductus deferens, cells in uterus, oviduct, germinal epithelium of ovary, and 
many others (Stumpf 1995a). After the identification of these different target tissues, an 
additionally important observation was the existence of a hierarchy of receptor binding and 
affinities, reflected also in different capacities for saturation (Koike et al. 1998a). The target 
tissues involved in systemic calcium regulation such as epithelia of the intestine and kidney 
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distal tubules as well as parathyroid chief cells (Stumpf et al. 1979a) belong to the cell 
populations with the highest affinity and binding capacity for vitamin D and OCT. This suggests 
a high response capacity at low blood levels and high effects at normal blood levels. Analogues 
of 1,25(OH)2D3, such as OCT (Murayama et al. 1986), have been developed with the goal of 
modifying pharmacokinetics, and thus achieving changes in target response. This study was 
designed to obtain information as to whether and to what degree changes in binding to vitamin 
D plasma binding protein and to parathyroid target cells occur when 1,25(OH)2D3 and OCT are 
compared, utilizing receptor micro-autoradiography. 
 
Materials and methods 
The present study was carried out in accordance with Chugai Pharmaceutical’s ethical 
guidelines of animal care, and the research protocols were approved by the animal care 
committee of the institution.  
 Eight-week-old male ddY strain mice (Japan SLC, Inc., Shizuoka, Japan), weighing 25-30 g, 
kept on a 14-h light and 10-h dark schedule, were fed normal chow (CE-2) and water ad libitum. 
[26-3H]OCT (specific activity 159.5 µCi/µg, Chugai Pharmaceutical Co., Ltd. Gotemba, 
Shizuoka, Japan) (Watanabe et al. 1995) or [26,27-methyl-3H]1,25(OH)2D3 (specific activity 
396.1 µCi/µg, Dupont/NEN Research Products, USA), of which the specific activity was 
adjusted to 159.5 µCi/µg with unlabelled 1,25(OH)2D3 (Wako Pure Chemical Industries, Ltd, 
Tokyo), were dissolved in ethanol-isotonic saline (1% ethanol, 0.01% Tween 20), and injected 
into the tail vein at a dose of 4 µg/kg. Two mice for each condition were killed under ether 
anaesthesia at 5, 15, 30 min, 1, 2, 4, 8, 12, and 24 h after injection.    
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Plasma concentration 
Blood was collected from the aorta, then centrifuged at 3000 r.p.m. for 10 min, and 0.1 g of 
plasma was used for combustion using a sample oxidizer (Model ASC-113, Aloka Co., Ltd, 
Tokyo). The radioactivity captured by Clear Sol I was measured using a liquid scintillation 
counter. Radioactivity concentrations were expressed as equivalents of OCT. 
 
Micro-autoradiography 
Samples of thyroid-parathyroid were excised, freeze-mounted on tissue holders after being 
frozen using isopentane cooled with liquid nitrogen, and sectioned at a 4-µm thickness. The 
sections were thaw-mounted on nuclear emulsion (Konica NR-M2)-coated slides exposed for 4 
months in refrigerator, then photographically processed and stained with methylene blue-basic 
fuchsin. The thaw-mount autoradiographic technique has been described in detail (Stumpf 1976). 
Autoradiograms were evaluated by computer-assisted image analysis using the Olympus Image 
Analysis System SP-500. The number of silver grains per nucleus was counted in all the chief 
cells of a defined region (75-115 cells each) and, after background subtraction, the mean 
number of silver grains per nucleus was determined. 
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Results 
After the injection of [3H]OCT or [3H]1,25(OH)2D3, the plasma concentration of [3H]OCT was 
lower in comparison with that of [3H]1,25(OH)2D3 (Figure 1). Nuclear uptake and retention of 
radioactivity in chief cells were present throughout the parathyroid gland at all time intervals 
(Figure 2), whereas connective tissue cells were unlabelled (Figure 3). After [3H]OCT injection, 
nuclear uptake was rapid and highest at 15 min (mean, 15.4 silver grains per nucleus; Table 1). 
After [3H]1,25(OH)2D3 injection, initial uptake was lower and the maximal nuclear 
concentration was reached later, at 1 h (mean, 9.4 silver grains per nucleus; Table 1). Both 
compounds had similar nuclear radioactivity at 2 h, and then parallel a decline with low levels 
was reached at 12 h with traces still visible at 24 h.  
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Discussion 
Evidence for cytoplasmic content and nuclear binding of 1,25(OH)2D3 was reported for chick 
parathyroid gland as early as 1975 (Brumbaugh et al, 1975), in parallel with observations on 
decreases in serum immunoreactive parathyroid hormone and parathyroid hormone secretion 
due to 1,25(OH)2D3 in vitro (Chertow et al. 1975). The results of the present study were in 
agreement with the previous autoradiographic studies, which demonstrated vitamin D receptor 
binding in chief cells (Stumpf et al. 1979a, Stumpf and O’Brien 1987). In general, there is 
strong nuclear receptor binding of vitamin D and analogues to calcitropic tissues, like 
parathyroid chief cells, kidney distal tubule epithelium, osteoblasts, and absorptive epithelium 
of the intestine. However, in the same animals the nuclear receptor binding was also observed in 
numerous tissues that appeared unrelated to systemic calcium regulation, such as central and 
peripheral nervous system, immune system, pituitary peripheral endocrine system, exocrine 
glands, skin, and reproductive system (Stumpf 1995a). Accordingly, during treatment of 
hyperparathyroidism with vitamin D or its analogues, like OCT, the activation of all vitamin D 
target tissues must be considered. Effects on non-calcitropic tissues are likely to be beneficial 
and may help to improve the general condition of the patient beyond the calcitropic effects on 
parathyroid, intestinal epithelium, and bone.   
 In these autoradiographic studies, the nuclear concentration of [3H]1,25(OH)2D3 was 
demonstrated in chief cells but not in connective tissue cells (Stumpf et al. 1979a, Stumpf and 
O’Brien 1987). [3H]OCT was localized similarly to [3H]1,25(OH)2D3 in the parathyroid. 
Biological and histochemical observation indicate that OCT binds to the same receptor as 
1,25(OH)2D3 and unlabelled 1,25(OH)2D3 prevents [3H]OCT from accumulating in target nuclei 
and vice versa. In comparative studies in rats, the in vivo saturation of nuclear receptor binding 
in parathyroid chief cells was reached after systemic injection at 1-2 µg/kg, a much lower dose 
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than in epidermal keratinocytes (4-6 µg/kg), or in kidney proximal tubule cells (8 µg/kg). The 
nuclear accumulation of radioactivity increased in a dose-related fashion towards a plateau. In 
contrast, extranuclear radioactivity levels did not reach a plateau but linearly increased. This 
supports the conclusion reached in the present study of a high affinity of parathyroid cells for 
OCT (Koike et al. 1998a).  
 Quantitative comparisons of in vivo nuclear binding to specific target cell populations, similar 
to the present histochemical studies, need to be performed with more animals and with different 
target tissues. Differences in OCT and 1,25(OH)2D3 nuclear binding affinities and kinetics have 
been reported between duodenal absorptive epithelium and gastric gland neck mucous cells 
(Stumpf et al. 1995c). Such differences in binding may reflect target-specific metabolism or 
even different receptor types. Their histochemical identification engenders functional and 
therapeutic considerations and can be of predictive value.  
 Our results of differential binding to nuclear receptor with rapid and high uptake of OCT 
compared with a delayed uptake of [3H]1,25(OH)2D3 and a tendency toward faster release of 
[3H]OCT are in correspondence with differences in the binding affinities to plasma protein of 
the two compounds. It is noteworthy that nuclear receptor occupation is sustained for several 
hours, despite low blood levels. The lower binding affinity of OCT to vitamin D binding protein 
(1/600) than that of 1,25(OH)2D3 suggests an easier release from the protein and an increased 
availability to the vitamin D receptor (Kobayashi et al. 1994). The maximum concentration of 
[3H]OCT in nuclei of parathyroid chief cells is 1.5-fold higher than that of [3H]1,25(OH)2D3 at a 
dose of 4 µg/kg. While this dose is higher than the clinical dose, pharmacokinetic parameters 
keep linearity from 0.1 to 10 µg/kg in normal rats (data not shown). Clinical treatment would 
allow doses of OCT up to 10 times those of 1,25(OH)2D3 because of the low calcaemic effect 
(Koshikawa et al. 2000, Kurokawa et al. 2000). Therefore, nuclear uptake of OCT will be higher 
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than that of 1,25(OH)2D3 under clinical conditions. This higher amount of nuclear uptake may 
be one explanation for the efficacy of OCT despite a 1.8-fold lower binding affinity to vitamin 
D receptor (Kobayashi et al. 1994).   
 17 
 
 
 
 
 
 
Fig 1. 
Plasma concentrations of radioactivity after i.v. administration of [26-3H]OCT or 
[26,27-methyl-3H]1,25(OH)2D3. Plasma concentration of [3H]OCT was lower than that of [3H] 
1,25(OH)2D3. ●, [26-3H]OCT; ○, [26,27-methyl-3H]1,25(OH)2D3. Each value represented the 
mean of two mice. *n=1.   
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Fig 2. 
Nuclear uptake of radioactivity represented by silver grain counts, in parathyroid chief cells 
after i.v. [26-3H]OCT or [26,27-methyl-3H]1,25(OH)2D3. Receptor binding of [3H]OCT rapidly 
increases, reaching a maximum at 15 min that was higher than that of [3H]1,25(OH)2D3, which 
was maximal at 1 h. 
●, [26-3H]OCT; ○, [26,27-methyl-3H]1,25(OH)2D3. Each value represented the mean of two 
mice. *n=1.   
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Fig 3. 
Autoradiograms of parathyroid gland showing time-course binding at (A) 5 min, (B) 15 min, 
(C) 1 h, (D) 24 h after injection of [26-3H]OCT, or at (E) 15 min, (F) 1h, (G) 24 h after injection 
of [26,27-methyl-3H]1,25(OH)2D3. The nuclear concentration and retention of radioactivity 
occurred in parathyroid chief cells at all time intervals, and was maximal at 15 min and 1 h for 
OCT and 1,25(OH)2D3, respectively, while connective tissue cells were unlabelled. Exposure 
time, 4 months. Frozen sections (4-µm) were stained with methylene blue-basic fuchsin. Bar = 
20 µm. 
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Table 1. 
Nuclear silver grain counts over parathyroid chief cells after i.v. administration of [3H]OCT and 
[3H]1,25(OH)2D3 
Time [3H]OCT [3H]1,25(OH)2D3
5 min 10.27 3.71
15 min 15.37* 3.78
30 min 12.45* 6.85
1h 11.24* 9.44
2h 7.02 7.81
4h 3.74 5.53
8h 1.75* 3.38
12h 1.45 1.76
24h 0.78 0.99
* n=1.
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CHAPTER 2 
In vivo dose-related receptor binding of the vitamin D analogue 
[3H]1,25-dihydroxy-22-oxavitamin D3 (OCT) in rat parathyroid, kidney 
distal and proximal tubules, duodenum, and skin, studied by quantitative 
receptor autoradiography 
 
Abstract 
1,25-Dihydroxy-22-oxavitamin D3 (OCT), is a new synthetic analogue of 1,25(OH)2D3 with a 
low calcemic effect. This study utilized quantitative receptor autoradiography to determine the 
dose-related receptor binding and saturation among the vitamin D target cells: parathyroid chief 
cells, kidney distal and proximal tubule epithelium, duodenal absorptive epithelium, and 
epidermal keratinocytes. Rats were injected with 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, 16.0 µg/kg bw of 
[26-3H]OCT and sacrificed 1 hr afterwards. Then autoradiographs were prepared under identical 
conditions. In these target cells, nuclear uptake of radioactivity increased with dose and then 
achieved a plateau. However, their saturation doses showed differences: parathyroid chief cells 
1-2 µg; duodenal absorptive epithelium, distal tubule epithelium, and epidermal keratinocytes 
4-6 µg; proximal tubule epithelium 8 µg (per kg bw). In contrast, in nontarget cells, such as 
liver and duodenal smooth muscle, radioactivity did not concentrate in the nuclei but increased 
in the cytoplasm with dose, without plateauing. These results provide the first information on 
the relative saturabilities of various target cell populations with a vitamin D ligand. Parathyroid 
chief cells required the relatively lowest receptor saturation dose. This suggests a high 
sensitivity and response to OCT treatment with related therapeutic potential for the regulation of 
parathyroid function.  
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Introduction 
1,25-Dihydroxy vitamin D3 [1,25(OH)2D3] has many biological effects beyond calcium 
regulation, such as suppression of parathyroid hormone (PTH) synthesis (Silver et al. 1985; 
Russell et al. 1986) and secretion (Cantley et al. 1985; Chan et al. 1986), regulation of cell 
differentiation and inhibition of cell proliferation in mouse and human myeloid cells (Abe et al. 
1981; Tanaka et al. 1982) and skin (Smith et al. 1986), stimulation of in vivo pituitary TSH and 
heart atrial natriuretic factor secretion (Stumpf 1995d), and in vitro adrenal medulla increase of 
tyrosine hydroxylase mRNA (Puchacz et al. 1996). However, the clinical use of 1,25(OH)2D3 is 
limited due to side effects caused by hypercalcemia. 
 1,25-Dihydroxy-22-oxavitamin D3 (OCT) is a synthetic analogue of 1,25(OH)2D3 that retains 
many of the therapeutically useful properties of 1,25(OH)2D3 but has less calcemic activity 
compared to 1,25(OH)2D3 (Nishii et al. 1991). OCT has also been shown to induce 
differentiation of WEHI-3 myelomonocytic cells (Abe et al. 1987), to inhibit proliferation of 
psoriatic fibroblasts (Morimoto et al. 1989), and to suppress PTH secretion and gene expression 
(Brown et al. 1989b; Naveh-Many and Silver 1993).  
 OCT has some different biological properties compared to 1,25(OH)2D3. The binding 
potencies of OCT to chick intestinal 1,2(OH)2D3 receptor (VDR) and serum vitamin D binding 
protein (DBP) were approximately 1/8 and 1/600 of the respective values of 1,25(OH)2D3 
(Kobayashi et al. 1994). OCT circulates as an intact form mainly bound to low-density 
lipoproteins (LDLs) (Teramoto et al. 1995). In addition, OCT reduces the plasma concentration 
of 1,25(OH)2D3 by suppression of the renal 25-hydroxy vitamin D3 1α-hydroxylase (Grieff et al. 
1992). However, OCT was demonstrated to bind to the same receptor as 1,25(OH)2D3 in 
developing bone (Stumpf et al. 1994), skin (Stumpf et al. 1995b), and stomach (Stumpf et al. 
1995c). 
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 OCT has been suggested to have various therapeutic potentials, e.g., for secondary 
hyperparathyroidism, psoriasis, and breast cancer (Abe et al. 1991), mimicking specific actions 
of 1,25(OH)2D3 in each of the target tissues without causing hypercalcemia. Therefore, a careful 
exploration of the in vivo target tissues for OCT is necessary to obtain further indications about 
the therapeutic potential for this low-calcemic vitamin D analogue. 
 To understand the mechanisms of vitamin D and its analogues, it is essential to know their 
target sites in vivo. Receptor autoradiography has high resolution and high sensitivity for the 
demonstration of ligand-receptor binding at the cellular-subcelluar light microscopic level 
(Stumpf 1976). Such information is difficult or impossible to obtain by radioassay using tissue 
homogenates, whole body autoradiography, imaging plate analysis, and in vitro studies with 
cultured cells. Thaw-mount receptor autoradiography permits the study of noncovalently bound 
hormones and drugs by avoiding translocation and leaching during histological tissue 
preparation, and has been used to identify target cells for 1,25(OH)2D3 in more than 50 different 
tissues (Stumpf 1995a). 
 The present study was designed to obtain information about relationships between the 
administered dose and the level of nuclear uptake and binding in select target cells after i.v. 
injection of [26-3H]OCT. Quantitative autoradiography combined with computerized image 
analysis was utilized. 
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Materials and methods 
The animals used in this experiment were treated in accordance with Chugai Pharmaceutical’s 
ethical guidelines, which adhere to generally accepted international criteria for humane 
treatment. Eight-week-old male Sprague-Dawley rats (JCL:SD; Japan Clea Laboratory, Tokyo, 
Japan) were fed normal rat chow (CE-2) and water ad libitum and kept under a 14:10 light-dark 
cycle. Two animals each were injected i.v. with 0.25, 0.5, 1.0, 2.0, 4.0, 8.0, or 16.0 µg/kg bw oｆ 
[26-3H]1,25-dihydroxy-22-oxavitamin D3 ([26-3H]OCT), with a specific activity of 76 Ci/mmol, 
dissolved in ethanol-isotonic saline (1% ethanol, 0.01% Tween 20). [26-3H]OCT was 
synthesized by the Chugai Pharmaceutical Co. with a purity better than 95%. One hour after the 
injection, duodenum, kidney, thyroid-parathyroid, skin, and liver were dissected, individually 
placed on tissue holders, and frozen in dimethylbutane cooled with liquid nitrogen, then stored 
in liquid nitrogen until sectioning in a microtome cryostat (Microm HM 500M; Heidelberg, 
Germany). The frozen sections at a thickness of 4 µm were thaw-mounted on nuclear emulsion 
(Konica NR-M)-coated slides and exposed in light-proof desiccator boxes at 4℃ for 1 month, 4 
months, or 15 months. After the exposure, slides were developed in Konicadol-X for 8 min at 
20℃, rinsed, fixed in Konicafix for 15 min at 20℃, rinsed, and stained with methylene 
blue-basic fuchsin, then air-dried and coverslipped. This thaw-mount autoradiographic 
technique has been described in detail (Stumpf 1976). 
 Competition studies were performed by co-injection of [26-3H]OCT at 2 µg/kg bw with a 
1000-fold excess of unlabeled 1,25(OH)2D3 (Wako Pure Chemical Industries; Osaka, Japan) or 
unlabeled OCT (Chugai Pharmaceutical Co.).  
  As additional controls against artifacts, autoradiographs from experimental tissues with 0-day 
exposure time were compared with autoradiographs with 1 month, 4 months, or 15 months of 
exposure time. There was no evidence for positive chemography. 
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 Quantitative analysis was performed with a computer-assisted image analysis system 
(Olympus SP-500) by counting the number of silver grains per nuclear area of all cells of a 
defined region (between 60 to 100 cells each in 10 fields of observation) with automatic 
background (extranuclear tissue radioactivity) subtraction. Background was calculated by 
multiplication of the number of silver grains per 100 µm2 (density) by nuclear area (size). 
Autoradiographs were evaluated at 1-month exposure time, because the clusters of silver grains 
increased at excess exposure and they caused loss of information for grain counting. 
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Results 
Cell Localization 
After the injection of [26-3H]OCT, specific cells (target cells) displayed a higher number of 
silver grains over the nuclear region compared to the cytoplasmic region. 
 
Parathyroid-Thyroid. Most of the parathyroid chief cells showed a high nuclear concentration 
of a radioactivity, i.e., silver grain levels were well above that of adjacent cytoplasm and 
extracellular space (Figure 1, 1-month exposure; Figure 2, 15-month exposure). Connective 
tissue cells of the parathyroid, in general, did not show nuclear accumulation of silver grains. In 
the adjacent thyroid tissue, radioactivity levels were low compared to the parathyroid chief cells 
(Figure 2). Thyroid follicle epithelial cells showed a slight elevation of cytoplasmic 
radioactivity compared to extracellular radioactivity levels. Occasionally, in follicle epithelial 
cells, a low to intermediate accumulation of nuclear radioactivity was noted. In the lumen 
(colloid) of small follicles, no or only very little radioactivity was present, whereas in the lumen 
of larger follicles radioactivity was accumulated, especially at the border of the follicle 
epithelium. This predominantly marginal radioactive labeling of the colloid increased in 
correlation with the increasing size of the follicles. Most of the extrafollicular cells did not show 
a nuclear accumulation of radioactivity, except for an occasional cell or group of a few cells 
with distinct nuclear labeling.  
 
Duodenum. Midportions of villi were selected. Absorptive epithelial cells exhibited nuclear 
accumulation of silver grains, in contrast to goblet cells and most of the connective tissue cells, 
which did not display nuclear labeling but exhibited only low levels of tissue “background” 
radioactivity (not shown).  
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Kidney. Among the various cell types in the kidney, the distal tubule epithelium showed the 
strongest nuclear labeling. In the proximal tubule epithelium, nuclear accumulation of 
radioactivity was also visible but was less intense than that in distal tubules. Glomerular 
podocytes and epithelial cells of the thick and thin limbs of the loop of Henle showed weak to 
intermediate nuclear labeling. In the cytoplasm of proximal tubule epithelium, silver grain 
density was high compared to the cytoplasm of adjacent distal tubule epithelium. Intertubular 
connective tissue cells were generally unlabeled (not shown). 
  
Skin. In epidermis, the strongest nuclear concentration of radioactivity was present in 
keratinocytes of the stratum spinosum (Figure 3, 1-month exposure). Cells of the basal layer of 
the epidermis showed relatively weak nuclear labeling under the conditions of the experiment. 
Labeled keratinocytes of hair follicles were not evaluated. Most of the fibroblasts of the dermis 
were devoid of nuclear labeling. 
 
Liver and Duodenal Muscularis Externa. Hepatocytes and smooth muscle cells did not show 
nuclear accumulation of radioactivity (Figure 4A, 1-month exposure; Figure 4B, 4-month 
exposure). 
 
Quantitative Evaluation of Autoradiographs 
The number of silver grains in nuclei of each target cell type is listed in Table 1. The nuclear 
accumulation of radioactivity increased in a dose-ralated fashion towards a plateau. The 
beginning of the plateau was reached for parathyroid chief cells at the lowest dose level of 
approximately 1-2 µg/kg bw and at 4-6 µg/kg bw for the other tissues, except for the proximal 
tubule epithelium, which follows approximately at 8 µg/kg bw (Figure 5A). In contrast, 
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extranuclear and extracellular radioactivity levels did not reach a plateau but increased almost 
linearly (Figure 5B). Nuclei and cytoplasm of hepatocytes of the liver (Figure 4A) and smooth 
muscle cells of the duodenum (Figure 4B) also showed a continuous increase of radioactivity 
without a plateau, although slightly higher nuclear radioactivity could be noted in hepatocytes 
when the nuclear density of silver grains was compared to that of the cytoplasm. 
 In the competition experiments with a 1000-fold excess of unlabeled 1,25(OH)2D3, nuclear 
concentration of radioactivity was abolished in parathyroid chief cells (Figure 1I and 2I), 
duodenal absorptive epithelium, kidney distal and proximal epithelium, and skin keratinocytes 
(Figure 3I). In contrast, silver grain densities over cytoplasm of target cells, extracellular 
compartments, nuclei and cytoplasm of hepatocytes, smooth muscle cells of the duodenum 
showed few or no changes.    
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Discussions 
In this study, quantitative receptor autoradiography was used to determine in vivo saturation 
doses for nuclear uptake of [26-3H]OCT by individual cell types of the parathyroid, duodenal 
villi, kidney proximal and distal tubules, and skin epidermis. 
 Autoradiography has high resolution and sensitivity for demonstrating ligand-receptor binding 
at cell levels compared with biochemical approaches at tissue levels. By quantitative 
immunoradiometric assay with tissue extracts, tissue levels of 1,25(OH)2D3 receptor were found 
to be highest in proximal small intestine and colon, containing 1000 fmol/mg total protein, 
where ileum and kidney contained one half and one forth of this amount, and 
thyroid/parathyroid, bone, and skin moderate levels of receptor of 40-80 fmol/mg (Sandgren et 
al. 1991). In contrast, by quantitative receptor autoradiography, target cell levels of OCT 
binding to VDR were relatively different. Because unlabeled 1,25(OH)2D3 prevented 
[26-3H]OCT from accumulating in nuclei, OCT may bind to the same receptor as 1,25(OH)2D3. 
At the maximal dose, the silver grain numbers over nuclei were highest in duodenal epithelium, 
high in kidney distal tubule epithelium and parathyroid chief cells, intermediate in kidney 
proximal tubule epithelium, and lowest in skin epidermis. The data obtained by the 
histochemical approach differ from those obtained by the biochemical immunoradiometric assay. 
Because the biochemical data are based on homogenized tissue extracts, different cell 
populations are lumped together and the ratio of target cell vs nontarget cell, such as parathyroid 
chief cells and thyroid follicle cells, may modulate or even obscure the desired information on 
receptor content. It is noteworthy that the parathyroid chief cells contain a relatively high 
amount of receptor-ligand binding among the target cells, when information is based on 
individual cell types and cell resolution.     
 Because OCT circulates mainly bound to LDL (Teramoto et al. 1995), the metabolic clearance 
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from blood (plasma T1/2) is shorter than that of 1,25(OH)2D3 bound to DBP. The plasma T1/2 
of OCT is 30 min after intravenous injection in rats (Dusso et al. 1991). However, it is 
noteworthy that nuclear receptor occupation remains at several hours (unpublished 
autoradiographic data) despite low blood levels. This study was performed at one hour after 
intravenous injection, when near-peak concentration exists in target cell nuclei. 
 Comparable histochemical or biochemical receptor saturation studies are not available in the 
literature for vitamin D, but exist for estradiol. When the data reported in this study are 
compared with those reported for estradiol, there is good correspondence regarding saturation 
dose range and differential of receptor saturability. Using a [3H]estradiol exchanged assay, 
Anderson et al. (1973) showed that uterine nuclear saturation occurs between 1.0 and 2.5 µg/rat. 
Using quantitative autoradiographic analysis of in situ [3H]estrogen concentration and saturation 
by individual cell types, one hour after intravenous injection, in the uterus and vagina nuclear 
silver grain numbers for six cell types increased with dose from 1.0 to 27 µg/kg bw when they 
plateaued. In the pituitary, four target cell types plateaued at 9 µg/kg bw, but thyrotropes at 3 
µg/kg bw. Both specific tissues, as well as their different cell types, reveal differences in 
saturation level and uptake capacity of [3H]estrogen in the mouse (Holderegger et al. 1981). 
 The results with [26-3H]OCT are in general agreement with those of [3H]estradiol, indicating 
in vivo saturate levels of nuclear receptor binding between 2 to 8 µg/kg bw for OCT and 3 to 9 
or 27 µg/kg bw for estradiol. These results together demonstrate a cell type-specific behavior of 
receptor-ligand binding, which is likely to be an important factor in the functional response of 
specific target cell populations. 
 Parathyroid chief cells required the lowest receptor saturation dose of [26-3H]OCT among the 
target cells. This low-dose receptor saturability indicates a high sensitivity of the parathyroid to 
treatment with OCT as well as 1,25(OH)2D3, because both compounds share the same receptor 
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(Stumpf et al. 1994, 1995b,c). This sensitivity of the parathyroid to vitamin D and OCT 
compound is reflected in the results of applications reported in the literature. 1,25(OH)2D3 
receptors are decreased in parathyroid glands in chronically uremic dogs (Brown et al. 1989a) 
and in patients with renal failure (Korkor 1987). OCT was able to prevent the decrease in 
vitamin D receptor content in parathyroid glands of uremic rats, even though its potency was 
less than that of 1,25(OH)2D3 (Denda et al. 1996). Secondary hyperparathyroidism in uremic 
patients was effectively suppressed by treatment with 1,25(OH)2D3 (Slatopolsky et al. 1984). 
Accordingly, the results of these clinical and experimental studies, together with the strong 
nuclear concentration of radiolabeled OCT in parenchymal cells of the parathyroid 
demonstrated in the present autoradiographic experiments, suggest a high therapeutic utility of 
OCT for the regulation of parathyroid function. OCT that binds to the same receptor as 
1,25(OH)2D3, with an apparent high affinity for the parathyroid, has much fewer systemic 
effects on plasma calcium levels than 1,25(OH)2D3 and is therefore less toxic than the parent 
compound in the treatment of parathyroid dysfunctions.  
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Fig 1. 
Autoradiographs of parathyroid (Figure 1, short exposure time), parathyroid with part of thyroid 
(Figure 2, long exposure time) and skin epidermis (Figure 3), showing dose-receptor binding 
relationships with increasing degrees of nuclear uptake of radioactivity and receptor saturation 
after injection of 3H-OCT, 0.25(A), 0.5(B), 1.0(C), 2.0(D), 4.0(E), 8.0(F), or 16(G) µg/kg bw. 
Competition with excess OCT (Figures 1H and 3H) or 1,25(OH)2D3 (Figures 1I, 2H, 2I, and 3I) 
prevents nuclear concentration of 3H-OCT. Exposure time, 1 month (Figures 1, and 3) and 15 
months (Figure 2). Four-µm frozen sections, stained with methylene blue-basic fuchsin. Bars = 
20 µm.   
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Fig 2. 
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Fig 3. 
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Fig 4. 
Autoradiographs of liver (A) and muscle of duodenum with parasympathetic neurons (B) as 
control nontarget tissues. Prepared from identical animals as used in Figures 1-3A-G. Exposure 
time, 1 month (A) and 4 months (B). Other conditions as in legend to Figures 1-3. Note absence 
of nuclear concentration of radioactivity in both tissues but high levels of radioactivity in 
cytoplasm of hepatocytes. Bar = 20 µm. 
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Table 1 
Dose-related nuclear receptor binding after in vivo administration of [3H]OCT in parathyroid, 
duodenum, skin, kidney, and liver prepared from autoradiographsa 
 
aOne hour after i.v. injection of [3H]OCT. Mean number of silver grains (SG over nuclei beforeb 
and afterc subtraction of extracellular tissue background (BG). SG were counted over at least 
100 cells for each structure in two rats for each condition. Cytoplasmic radioactivity was 
measured over muscle cells of the muscularis externa in duodenum and over hepatocytes.  
dCompetition with 1000-fold excess of OCT or 1,25(OH)2D3 injected together with 2.0 µg/kg of 
[3H]OCT suppressed or eliminated nuclear concentration of radioactivity.  
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Fig 5. 
In vivo nuclear receptor “saturation” (A) and nonsaturable uptake of radioactivity in 
extranuclear compartments of target tissues, smooth muscle of duodenum, and hepatocytes (B) 
after i.v. injection of [3H]OCT at a dose of 0.25-16 µg/kg body weight (n=2). Competition 
[3H]OCT 2 µg/kg + unlabeled OCT or 1,25(OH)2D3 2000 µg/kg. Evaluation of 
auitoradiographs: (A) % nuclear uptake calculated from amount of nuclear radioactivity 
(considered 100 % at 16 µg/kg) after subtraction of extranuclear “background” and (B) silver 
grain number in extranuclear regions of target tissues, and in nuclei and cytoplasm of 
hepatocytes. Note: (A) In parathyroid 90% nuclear saturation level is reached at a dose of 1-2 
µg/kg compared to 4-6(8) µg/kg in the other target tissues.  
 38 
CHAPTER 3 
In vivo nuclear uptake of a vitamin D analog (OCT) in different tumor cell 
populations of FA-6 cancer xenograft in nude mice by receptor 
autoradiography 
 
Abstract 
1α,25-Dihydroxyvitamin D3 (1α,25(OH)2D3) and its analogs have been shown to repress the 
production of parathyroid hormone-related peptide (PTHrP) in tumors, which is a major factor 
causing humoral hypercalcemia associated with various cancers. Since vitamin D analogs may 
be applicable to the treatment of cancer patients, the present study was undertaken to examine 
whether OCT, an analog with little calcemic activity, is incorporated into tumor tissues, and to 
identify cellular and subcellular sites of its specific uptake and retention. [26-3H]OCT was 
injected i.v. into nude mice inoculated with a human pancreatic carcinoma cell line (FA-6). At 1 
hour after the injection, intracellular concentration of radioactivity was visualized by receptor 
(thaw-mount) autoradiography. The results indicate a heterogeneous distribution of radioactivity 
in nuclei of certain large cancer cells as well as in single or clustered small and elongated cells 
within the tumor, while connective tissue cells outside of the tumor remained free of nuclear 
labeling. The data suggested that OCT acts selectively at the genome of cancer cells during a 
certain maturational stage and also of a second population of small fibroblast-like cells that may 
have been transplanted with the tumor or are host-derived. 
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Introduction 
In recent years various vitamin D analogs have been developed in an attempt to separate the 
calcemic activities from the actions on cell proliferation and differentiation in cancer cells 
(DeLuca 1988, Bouillon et al 1995). Among the analogs of 1α,25-dihydroxyvitamin D3 
(1α,25(OH)2D3),  1α,25-dihydroxy-22-oxavitamin D3 (OCT) has been synthesized in our 
laboratory and shown to inhibit cancer cell growth in vitro and in vivo with little calcemic 
activity (Abe et al 1991, Abe et al. 1986). It has also been demonstrated that OCT, as well as 
1α,25(OH)2D3, is capable of repressing the transcription of parathyroid hormone-related peptide 
(PTHrP) in cancer cells in vitro (Inoue et al. 1993) and that systemic administration of vitamin 
D analogs ameliorates the cancer-associated hypercalcemic syndrome caused by PTHrP in vivo 
(Endo et al. 1994, Haq et al. 1993).  
 The mechanism by which vitamin D analogs, such as OCT, exert a therapeutic effect in vivo is 
not fully understood. Although the presence of vitamin D receptor (VDR) in FA-6 tumors was 
confirmed by RNA analysis and binding assays with nuclear extracts of the tumor tissue (Endo 
et al. 1994), cellular and subcellular sites of binding and deposition remain to be clarified, in 
particular the type(s) of target cells in tumor tissue that bind and respond to treatment. 
 The present study was undertaken to identify target cells of OCT in tumor tissue in vivo in the 
nude mouse model carrying a human pancreatic carcinoma line, FA-6, using receptor 
autoradiography.  
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Materials and methods 
Chemicals. 
1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) was obtained from DUPHAR B.V., Holland. 
1α,25-dihydroxy-22-oxavitamin D3 (OCT) and [26-3H]OCT were synthesized at Chugai 
Pharmaceutical Co. (Murayama et al. 1986, Watanabe et al. 1995). 
 
Animals. 
Five-week-old male BALB/c nu/nu mice (SLC Japan, Tokyo) were transplanted with tumor 
tissues derived from human pancreatic cancer cells (FA-6; obtained from Dr. Naokazu Nagata, 
National Defense Medical College), fed normal rat chow (CE-2) and water ad lib, and kept 
under a 14/10 light-dark cycle. Three weeks after transplantation, animals with increased blood 
Ca2+ levels (between 1.59 and 3.09 mmol/L) were injected intravenously with 4.0 µg/kg body 
weight (bw) of [26-3H]OCT (specific activity 76 Ci/mmol) dissolved in ethanol-isotonic saline 
(5% ethanol, 0.01% Tween 20). One competition control animal was injected i.v. with 400 
µg/kg bw of unlabeled 1α,25(OH)2D3 together with 4 µg/kg bw of [26-3H]OCT. The current 
study was conducted in accordance with the ethical guidelines of animal care of Chugai 
Pharmaceutical Co., and the protocol was approved by the animal care committee of the 
institution.   
 
Receptor autoradiography. 
One hour after the injection, animals were sacrificed under ether anesthesia since the results of 
our previous study indicated that the uptake of OCT into the FA-6 tumor peaked 1 h after i.v. 
injection (Endo et al. 1994). Tumors as well as skin, as a classical target tissue for 
1α,25(OH)2D3, were removed and freeze-mounted on tissue holders by immersion in 
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dimethylbutane cooled with liquid nitrogen. Four µm frozen sections were cut in a microtome 
cryostat (Microm HM 500M, Heidelberg) and thaw-mounted on nuclear emulsion (Konica 
NR-M2, Tokyo)-coated slides. After exposure in light-proof desiccator boxes in a refrigerator, 
autoradiograms were developed in Konicadol-X for 8 min at 20℃, rinsed, fixed in Konicafix 
for 15 min at 20℃, rinsed, and stained with methylene blue-basic fuchsin, then air-dried and 
coverslipped. The thaw-mount autoradiographic technique has been described in detsail (Stumpf 
1976). As control against chemographic artifacts, 0-day exposure autoradiograms were 
compared with long-time exposed autoradiograms. 
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Results 
Cross sections of the FA-6 tumors showed circumscribed areas of large tumor cells that could be 
delineated from the surrounding subcutaneous connective tissue of the host. Within the tumor 
parenchyma, regions of cellular degeneration and blood imbibition could be recognized among 
apparently intact populations of large and rounded tumor cells. Strands of smaller and 
sometimes elongated cells were occasionally noted between clusters of tumor cells. 
 Radioactivity, visualized as developed silver grains, could be seen diffusely distributed 
throughout the tumor and host tissues. Certain tumor cells, usually arranged in groups and 
occurring in various regions of the tumor, displayed a nuclear concentration of radioactivity 
(Figure 1A), while other tumor cells contained little or no accumulation of nuclear radioactivity. 
There existed a great variety of nuclear radioactivity among the tumor cells in different regions 
of the same tumor. Occasionally, smaller and elongated cells concentrate radioactivity in their 
nuclei. These smaller cells appeared in groups (Figure 1B) or singly (Figure 1D and E), and 
could be seen at the edge of the tumor (Figure 1B), resembling components of a connective 
tissue septum. Tumor cells near or within decaying regions were usually devoid of nuclear 
labeling. 
 Samples of skin from the same animal, processed and exposed under the same conditions as 
the tumor tissue, showed nuclear concentration of radioactivity as reported earlier for skin 
keratinocytes (Stumpf et al. 1995b), similar to that observed in certain tumor cells. Controls 
against artifacts with 0-day exposure of autoradiograms did not show any nuclear silver grain 
localization or other evidence for positive chemography. In the competition experiment with 
100-fold excess of unlabeled 1α,25(OH)2D3, nuclear labeling was markedly reduced or 
eliminated (Figure 1C). 
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Discussions 
The demonstration of nuclear binding and retention of [26-3H]OCT in the present study is in 
agreement with the results from previous biochemical experiments that VDR mRNA is 
expressed in FA-6 tumor and that nuclear extracts of whole tumor tissue contain a binding 
activity for OCT as well as 1α,25(OH)2D3 (Endo et al. 1994). The concentration of radioactivity 
in nuclei is in agreement with the classic concept that vitamin D and its analogs complexed with 
VDR bind to DNA, known as a vitamin D response element (VDRE), as a heterodimer with 
retinoid X receptor (RXR), and modulate the transcription rate of target genes (Alroy et al. 
1995). In addition, vitamin D may be incorporated in a VDR-independent fashion, such as a 
low-density lipoprotein (LDL) receptor-mediated pathway after its complex formation with 
LDL (Teramoto et al. 1995), especially into cancer cells that demand cholesterol as their energy 
source.  
 We have also demonstrated in the present study that the nuclear uptake of the vitamin D 
analog is not uniform. Nuclear receptor binding appears to be limited to or maximal in certain 
cancer cells, but is reduced or absent in other cancer cells, in particular near or in decaying 
regions. This suggests changes of VDR expression in relation to the developmental stage of 
neoplastic cells within the heterogeneous tumor cell population. 
 Interestingly, nuclear uptake of OCT was also observed in a cell population different in 
appearance from the large cancer cells. In addition to the ubiquitously distributed large and 
rounded clustered cells with prominent nucleoli, a less frequent population of smaller elongated 
cells, resembling fibroblasts, could be identified with nuclear concentration. Some of these 
small target cells exist in strands, in small groups, or singly, and resemble septal connective 
tissue interspersed between clusters of larger epitheloid tumor cells. Since such ‘septal’ target 
cells are sometimes associated with the edge of the tumor, a host-derived origin of these ‘tumor’ 
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cells may be considered. Since multiple target cell populations exist within the same tumor, their 
role and relationship to each other during different stages of tumor growth, angiogenesis, and 
response to treatment requires further elucidation.  
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Fig 1. 
Autoradiograms showing nuclear uptake of [26-3H]OCT in tumor tissue. 
[26-3H]1α,25-dihydroxy-22-oxavitamin D3 ([26-3H]OCT) was administered i.v. to nude mice 
carrying human pancreatic cancer (FA-6). Concentration of radioactivity in nuclei (arrows) of 
large tumor cells (A), small cells between clusters of large cells at the edge of the tumor (B), 
and single fusiform cells (D and E) is shown. Competition with excess 1,25(OH)2D3 prevents 
nuclear concentration of 3H-OCT (C). Four µm frozen sections were cut and stained with 
methylene blue-basic fuchsin. Bars = 10 µm (A,B,D,E), 20 µm (C). Exposure time = 9 months.  
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CHAPTER 4 
Sweat gland epithelial and myoepithelial cells are vitamin D targets 
 
Abstract 
Nuclear receptor binding of 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) in skin kerathinocytes of 
epidermis, hair sheaths and sebaceous glands was discovered through receptor microscopic 
autoradiography. Extended experiments with 3H-1,25(OH)2D3 and its analog 3H-oxacalcitriol 
(OCT) now demonstrate nuclear receptor binding in sweat gland epithelium of secretory coils 
and ducts as well as in myoepithelial cells, as studied in paws of nude mice after i.v. injection. 
The results suggest genomic regulation of cell proliferation and differentiation, as well as of 
secretory and excretory functions, indicating potential therapies for impaired secretion as in 
hypohidrosis of aged and diseased skin.  
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Introduction 
Skin was recognized as a vitamin D target in 1979 through in vivo exploration of adult, neonatal 
and fetal rodents with the sensitive method of receptor microscopic autoradiography (Stumpf et 
al. 1979a). The distribution of vitamin D receptor-binding sites corresponds in part to that of 
estradiol in keratinocytes. It differs from that of estradiol especially in fibroblasts of the dermis. 
Estradiol concentration predominates in fibroblasts, including those of dermal papillae of hair 
(Stumpf et al. 1974). While vitamin D nuclear concentration is weak or absent in fibroblasts, 
under the same conditions it is strongest in keratinocytes of outer hair sheaths (Stumpf et al. 
1979a, 1984).  
 Using receptor microautoradiography, for vitamin D over 50 target tissues have been identified 
and characterized (Stumpf 1995a). This positions vitamin D as a polyfunctional hormone, 
similar to sex and adrenal steroids. Most of the vitamin D target tissues, including those in skin, 
are unrelated to the regulation of systemic calcium, instead serving functions primarily related 
to seasonal adaptation for survival, growth and reproduction that involves regulation of 
proliferation and differentiation of certain tissues, of exo- and endocrine secretion, and of 
immune, stress, cardiovascular, sensory, neuromuscular, and other tissue responses (Stumpf 
1995a).  
 For the histochemical identification of vitamin D target cells in skin two methods have been 
used and reported in the literature: receptor microautoradiography with radiolabeled agonists 
(Stumpf et al. 1979a, 1974, 1984 1993), and immunocytochemistry with antibodies to receptor 
protein (Stumpf et al. 1993, Milde et al. 1991, Reichrath et al. 1994, Reichrath et al. 1996). 
While there seems to be general correspondence of the results, in comparative studies 
occasionally differences in resolution and sensitivity are apparent. Variations in 
immunocytochemical data have been attributed to the use of different antibodies and to tissue 
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treatment with different fixatives, related denaturation, and changed access to epiｔopes (Stumpf 
1995a, Reichrath et al. 1996). 
 In the present experiments, receptor microautoradiography (Stumpf 2003) was used for the 
study of sweat glands in mouse paws to identify vitamin D-specific receptor sites of 
concentration and retention. To elucidate and understand drug function, discoveries and 
characterization of site of specific drug binding are essential. 
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Materials and methods 
Nude mice with tumor transplants were used for the simultaneous study of receptor binding in 
different target and non-target tissues. The results of the tumor distribution have been published 
(Koike et al. 1999).  
 Five-week-old male BALB/c nu/nu mice (SLC Japan, Tokyo, Japan) were transplanted with 
tumor lumps of human pancreatic cancer cells (FA-6), fed normal rat chow (CE-2) and water ad 
lib, and kept under a 14/10 light-dark cycle. Three weeks after transplantation, each of two 
animals with increased serum Ca-levels between 1.59 and 3.09 mmol/L, were injected 
intravenously with 4 µg/kg bw of [26-3H]OCT (Chugai Pharmaceutical Co., Tokyo, Japan) with 
a specific activity of 76 Ci/mmol or 4 µg/kg bw of [26,27-3H]1,25(OH)2D3 (Amersham, 
Chicago, IL, USA) with a specific activity of 163 Ci/mmol, adjusted to the specific activity of 
[26-3H]OCT by dilution with unlabeled 1,25(OH)2D3 (Duphar B.V., Weesp, Holland), dissolved 
in ethanol-isotonic saline (5% ethanol, 0.01% Tween 20).  
 Competition control was performed under identical conditions. One additional nude mice was 
injected i.v. with 400 µg/kg bw of unlabeled 1,25(OH)2D3 together with 4 µg/kg bw of 
[26-3H]OCT. 
 One hour after the injection, animals were killed under ether anesthesia, front paws were 
removed and freeze-mounted on tissue holders (two for each sample) by immersion in 
isopentane cooled with liquid nitrogen. Frozen sections (4 µm) were cut in a microtome cryostat 
(Microm HM 500M; Microm, Walldorf, Germany) and thaw-mounted on nuclear emulsion 
(Konica NR-M2; Konica, Tokyo, Japan)-coated slides. After exposure in lightproof desiccator 
boxes in a refrigerator, autoradiograms were developed in Konicadol-X for 8 min at 20℃, 
rinsed, fixed in Konicafix for 15 min at 20℃, rinsed, and stained with methylene blue-basic 
fuchsin, then air-dried and coverslipped. The method of receptor microautoradiography has been 
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developed in our laboratories and described in detail (Stumpf 2003). 
 As control against chemography artifacts, 0-day exposed autoradiograms were compared with 
long-time exposed autoradiograms. Zero-day autoradiograms did not show any nuclear 
concentration of developed silver grains. To assess the effect of competition, silver grains over 
the nuclear areas of 20 cells of sweat gland epithelium were counted in each animal, and the 
mean numbers of silver grains per nuclear area were compared with each other. 
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Results 
In the autoradiograms (Figs 1-3), selective nuclear concentration of radioactivity can be 
recognized in epithelial cells in both distended and narrow portions of sweat glands, involving 
both secretory coils and ducts (Figs 1 and 2). Myoepithelial cells can be identified by their 
marginal position and show nuclear labeling similar to that of adlumenal epithelia cells. In the 
same preparation, fibroblasts and striated muscle cells do not show nuclear concentrations of 
radioactivity.  
 The pattern of nuclear concentration appears similar for 3H-OCT and 3H-1,25(OH)2D3. In the 
competition experiment (Fig. 3) with 100-fold excess of unlabeled 1,25(OH)2D3, nuclear uptake 
and retention after 3H-OCT is reduces to 30%. 
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Discussions 
The results of the present experiment demonstrate the presence of nuclear uptake and retention 
of radiolabeled compound after injection of tritium-labeled 1,25(OH)2D3 or its analog [3H]OCT 
in epithelial and myoepithelial cells of sweat glands, while no such concentration exists in 
connective tissue, striated muscle and fat cells in the vicinity of the glands. These results 
correspond to previously recognized select nuclear concentration in keratinocytes of the 
epidermis, hair sheaths, hair bulbs, sebaceous glands, and mammary gland epithelium (Stumpf 
et al. 1995b). In the skin, the strongest nuclear concentration of vitamin D compounds exists in 
the outer hair sheaths, followed by basal cells in sebaceous glands and cells in the stratum 
spinosum, granulosum, and basale of the epidermis, but – under the same experimental 
conditions – not found or found to be very weak in hair dermal papillae, fibroblasts, fat cells and 
muscle cells of the dermis and hypodermis. While fibroblasts appear mostly unlabeled with 
vitamin D, except in some regions like the infundibulum of vibrissae, 3H-estradiol concentrates 
not only in keratinocytes but most strongly in fibroblasts including cells of dermal papillae 
(Stumpf et al. 1974).  
 As mammary gland epithelium also shows nuclear concentration of 1,25(OH)2D3 (Narbaitz et 
al. 1981), it may be assumed that apocrine glands behave similarly. Therefore, functions of all 
appendices of the skin appear genomically regulated to varying degrees by vitamin D. The 
different degrees of nuclear concentration and the related hierarchy of steroidal effects remain to 
be assessed. Evidence for differential receptor occupation and related functional activation is 
suggested from the results of previous quantitative autoradiographic studies with other vitamin 
D target tissues, thus demonstrating the need for detailed assessment of individual target 
pharmacokinetics (Stumpf 2005).    
 The results of the present autoradiographic studies extend those obtained with antibodies to 
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vitamin D receptor in human skin that showed immunohistochemical nuclear staining in sweat 
gland epithelium (Berger et al. 1988).  
 The functional significance of vitamin D receptor binding to sweat gland secretory and 
myoepithelial cells remains to be elucidated. Based on the present findings and actions of 
vitamin D on other tissues and glands, it can be assumed that secretory and excretory activities, 
cell proliferation and differentiation, as well as myoepithelial effects are all regulated by 
1,25(OH)2D3 in correspondence to seasonal changes in hormone precursor blood levels and the 
related modulation of cellular responses (Stumpf and Privette 1991).   
 In human eccrine sweat glands, two secretory cell types have been described. These cell types 
are, however, transitional in their ultrastructure and organelles. Only one secretory cells type 
exists in mice and rats, dark mucous cells are absent in rodents (Quick et a. 1984, Mykytowycz 
R. 1972, Munger and Brusilow 1970). The variations in the intensity of nuclear radioactivity 
labeling noticed in the present studies nonetheless may reflect certain differences in 
cellular-subcellular composition and activities of the secretory cells.  
 Available evidence suggests that the ubiquitous human sweat glands primarily serve 
thermoregulation with their secretions of less behavioral importance. By contrast, the 
paw-restricted rodent glands primarily deposit scent signals as territorial markers with odors for 
individual and group identification (Mykytowycz R. 1972). 
 The functions of skin appendages that include eccrine glands, apocrine and sebaceous glands, 
as well as hair, apparently are modified by sex steroids correlated with seasonal changes through 
vitamin D levels (Stumpf and Privette 1991). Evidence for close interaction between sex 
steroids and vitamin D can be gleaned from corresponding receptor binding demonstrated for 
numerous target cell populations not only in the skin but also in atrial cardiac myocytes, thymus 
reticular cells, and neurons in the preoptic-septal-amygdaloid-hypothalamic continuum, anterior 
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and posterior pituitary, and others (Stumpf 1995a). 
 Involvement of vitamin D in scent-related regulation of sexual behavior is further suggested by 
the existence of vitamin D-target cells in the vomeronasal organ (W.E. Stumpf, unpublished 
data), which is linked to estradiol and vitamin D target neuron regions in projections of the stria 
terminalis in the amygdale and septal-preoptic area (Stumpf and Grant eds. 1975). 
 The present autoradiographic evidence for vitamin D nuclear receptor binding enables 
functional follow-up, with possible significance for pathologic conditions associated with sweat 
glands, such as cystic fibrosis with its decreased NaCl ductal absorptive function; sweat gland 
adenomas with both epithelial and myoepithelial cells present; and various forms of hypo- and 
hyperhidrosis (Sato et al. 1989). 
 Pharmacologic utilization of the demonstrated conditions is an attractive possibility that 
deserves consideration and exploration. In addition to cosmetic applications, treatment of aging 
skin (Fenske and Loher 1986) and certain disease may be explored (Lehmann et al. 2004), 
including forms of ectodermal dysplasia, hypo- and oligohidrosis, which could be similar to the 
promising results shown for forms of scleroderma (Ronger et al. 2003). Regarding hypohidrotic 
ectodermal dysplasia, it is interesting to note that the tissues that constitute the congenital 
disorder in sweat glands (hypohidrosis), hair (hypotrichosis), and teeth (hypodontia) (Blecher 
1986), also involving the immune system (Huntley and Ross 1981), all contain targets for 
vitamin D (Stumpf 1995a). Certain forms of these disease conditions may benefit from 
preventive-therapeutic treatment with vitamin D or its analogs. As can be expected, 
hypervitaminosis D can exert toxic effects on sweat glands and other vitamin D targets in skin 
(Gimeno et al. 2000). Depending on the dose applied, both conditions of hypo- or hyperhidrosis 
may respond therapeutically, related to enantiodromic polarity and hormetic reversal of drug 
actions (Stumpf 2006). 
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Figs 1-3. 
Autoradiograms of sweat glands, 1 h after i.v. injection of [26-3H]OCT in nude mice, showing 
nuclear concentration of radioactivity in secretory epithelium of tubular glands (Figs 1 and 2) 
and duct (Fig. 2, open arrow), as well as in myoepithelial cells (Fig. 1, arrows). In competition 
experiment with simultaneous injection of 100-times excess unlabeled 1,25(OH)2D3, nuclear 
labeling is reduced or abolished (Fig. 3). Four µm frozen sections, stained with methylene 
blue-basic fuchsin. Magnification: x530 (Fig. 1), x350 (Fig. 2), x875 (Fig. 3). Exposure time: 3 
months (Fig. 1), 12 months (Fig 2 and 3).  
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CHAPTER 5 
Sustained osteoblast nuclear receptor binding of converted 
1α,25-dihydroxyvitamin D3 after administration of 3H-1α-hydroxyvitamin 
D3: A combined receptor autoradiography and radioassay time course study 
with comparison to 3H-1α,25-dihydroxyvitamin D3 
 
Abstract 
The present study was undertaken to clarify the receptor distribution and the pharmacokinetics 
of 3H-1α(OH)D3, and 3H-1 α,25(OH) 2D3 for comparison. Receptor autoradiography was used 
after intravenous injection to 3-day-old neonatal rats and radioassay-HPLC after oral application 
to young adult rats. Corresponding results were obtained from both receptor autoradiography 
and radioassay. After 3H-1α(OH)D3 administration, uptake was delayed but sustained over a 
long period of time and the concentration of silver grains (autoradiography) or recovered 
3H-1 α,25(OH) 2D3 (radioassay) peaked at a low level. After 3H-1 α,25(OH) 2D3 administration, 
osteoblast nuclear, whole bone uptake and retention of radiolabeled compound were relatively 
rapid and short in duration. Nuclear uptake in osteoblasts after administration of 3H-1α(OH)D3 
was abolished in competition studies with 10-fold unlabeled 1 α,25(OH) 2D3. These results 
indicate that 1α(OH)D3 continuously supplies osteoblasts with converted 1 α,25(OH) 2D3 and 
would not spread to the cells because of the low binding affinity of the receptor. Accordingly, 
1α(OH)D3 appears to have some therapeutic properties different from 1α,25(OH) 2D3 because 
of a relatively slow and sustained accumulation of the receptor and less Cmax (pharmacokinetics) 
compared with 1α,25(OH) 2D3. 
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Introduction 
1 α,25-Dihydroxyvitamin D3 (1 α,25(OH)2D3) is metabolized from vitamin D3, first by 
25-hydroxylated in the liver (Ponchon et al. 1969), and second by 1α-hydroxylated in the kidney 
(Lawson et al. 1971). Patients with chronic renal failure have a continuous lack of 
1 α,25(OH)2D3 because of decreased 1α-hydroxylase activity in the kidney (Feinfeld and 
Sherwood. 1988). Therefore, 1α-hydroxyvitamin D3 (1α(OH)D3) was chemically synthesized 
(Barton 1973) and applied as a pro drug (Holik et al. 1973) for the treatment of patients with 
renal failure to alleviate their symptoms of vitamin D deficiency. Also, 1α(OH)D3 has been used 
successfully for the treatment of patients with osteoporosis (Takuo 1992, Civitelli 1995).  
 1α- and 24-Hydroxylase activities for 25-hydroxyvitamin D3 (25 OHD3) have been reported in 
human bone cells (Howard et al. 1981) similar to kidney cells. Recently, vitamin D3 
25-hydroxylase activity has also been noted in mice bone cells (Ichikawa et al. 1995) in addition 
to its existence in the liver. 
 Receptor autoradiography is a powerful method for determining in vivo target cells for steroid 
hormones such as vitamin D (Stumpf 1976). Target cells for  1α,25(OH)2D3 have been 
demonstrated in intestine, kidney, stomach, skin, pituitary, parathyroid (Stumpf et al. 1979a), 
brain (Stumpf and O’Brien 1987b), and many other tissues (Stumpf 1995a), including bone 
(Narbaitz et al. 1983) and teeth (Kim et al. 1985). There are only a few reports, however, for 
bone and teeth, because of problems related to technique, such as cutting of undecalcified bone 
and artifacts related to decalcification and fixation tissue treatments. In a recent 
autoradiographic study, we demonstrated the cellular and topographical distribution of 
3H-1,25(OH)2D3 and 3H-22-oxacalcitriol, a 22-oxygenated analog of 1α,25(OH)2D3, in neonatal 
rat bone (Stumpf et al. 1994).  
 The present experiment was designed to investigate whether there is evidence for receptor 
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binding in bone of 3H-1α(OH)D3 or/and converted 1α,25(OH)2D3. We examined the in vivo 
time course by receptor autoradiography and by radioassay with 3H-1α(OH)D3 and 
3H-1α,25(OH)2D3. 
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Materials and methods 
The animals used in this experiment were treated in accordance with Chugai Pharmaceutical’s 
ethical guidelines with adhere to generally accepted international criteria for human treatment. 
 
Receptor Autoradiography 
 
Three-day old male Sprague-Dawley (SD) rats (SLC, Shizuoka, Japan) were used for this study. 
Three animals each were injected intravenously at 2.0 µg/kg body weight of 
[26,27-3H]1α,25(OH)2D3 (specific activity 164.0 Ci/mmol, Dupont, Boston, MA, USA) or 
[22,23-3H]1α(OH)D3 (unpublished data) (specific activity 111.5 Ci/mmol, Chugai 
Pharmaceutical Co. Ltd.), dissolved in ethanol-isotonic saline (5% ethanol, 0.01% Tween 20). 
At periods of 2, 8, 24, and 48 hours after the injection, hind legs with tibia and knee joint, 
frozen with liquid nitrogen, were sectioned at 3 µm thickness without decalcification. The 
frozen sections mounted on nuclear emulsion (Konica NR-M2)-coated slides were exposed for 
4 months, developed, fixed, rinsed, and then stained with methylene blue-basic fuchsin. This 
thaw-mount autoradiographic technique has been described in detail (Stumpf 1976). 
 Competitive study was performed by co-injection of 3H-1α(OH)D3 with 10-fold unlabeled 
1α,25(OH)2D3, and 3H-1α,25(OH)2D3 with 9-fold unlabeled 1α,25(OH)2D3. Rats were 
sacrificed 2 hours after the co-injection. The autoradiograms were evaluated using a number of 
silver grains in nuclei by a computer-assisted image analysis system (SP-500, Olympus, Tokyo, 
Japan). The mean number of silver grains per nucleus was determined from 50 or more cells, 
with automatic subtraction of extracellular “background” silver grains. 
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Radioassay-HPLC 
 
Seven-week-old male SD rats (Charles River, Kanagawa, Japan) were fed CE-2 chow and water 
ad libitum. [1β-3H] 1α(OH)D3 (Holick et al. 1980) was synthesized (specific activity 9.2 
Ci/mmol, Chugai) and [26,27-3H]1α,25(OH)2D3 was purchased from DuPont (specific activity 
166 Ci/mmol). These labeled compounds were purified by HPLC prior to use and specific 
activity of 3H-1α,25(OH)2D3 was adjusted with unlabeled 1α,25(OH)2D3 (Duphar, Netherlands) 
to that of 3H-1α(OH)D3. The labeled compounds were dissolved at a concentration of 1.08 
µg/25 µCi/mL in medium chain triglyceride and were orally administered by gastric catheter at 
1 mL/kg body weight. Rats were sacrificed under ether anesthesia at 12, 24, 48, 72, and 96 
hours after administration, and blood and long bone were collected to extract radioactivity. 
Plasma was separated from blood by centrifugation. Bone marrow was removed by rinsing. 
Radioactivity from samples separated 3H-1α,25(OH)2D3 fraction with HPLC (column: 
µ-porasil; waters, eluent: 10% isopropanol/n-hexane). The fraction, which co-migrated with 
authentic 1α,25(OH)2D3, was collected for determination of radioactivity with a liquid 
scintillation counter (LSC-900, ALOKA). 
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Results 
 
Receptor Autoradiography 
 
After injection of 3H-1α(OH)D3 or 3H-1α,25(OH)2D3, certain cells displayed a relatively high 
number of silver grains over their nuclear region when compared with other cells such as their 
cytoplasm, or extracellular compartments. The time-related degree of nuclear uptake and 
retention was characteristic for the labeled compounds (Fig. 1A-H). 
 Nuclear concentration of radioactivity was recognizable in certain osteoblasts and 
chondrocytes in bone samples. The patterns of distribution of target cells was similar for 
3H-1α(OH)D3 and 3H-1α,25(OH)2D3, and the same hierarchy of relative nuclear labeling 
intensity existed for the two compounds, as judged by the number of silver grains. 
 Radioactive nuclear labeling after injection of 3H-1α(OH)D3 was low at 2 hours (Fig. 1A), 
strongest at 8 hours (Fig. 1C), and sustained at low levels until 48 hours (Fig. 1G). In contrast, a 
strong uptake of radioactivity after 3H-1α,25(OH)2D3 injection existed at 2 hours (Fig. 1B) and 
8 hours (Fig. 1D), but was low or undetectable at 24 (Fig. 1F), and 48 hours (Fig. 1H). By 
co-injection of 3H-1α(OH)D3 with 10-fold unlabeled 1α,25(OH)2D3, (Fig.1I), and  
3H-1α,25(OH)2D3 with 9-fold unlabeled 1α,25(OH)2D3 (Fig. 1J), the specific nuclear 
distribution of silver grains decreased when comparing Fig. 1I with Fig. 1A, or Fig. 1J with Fig. 
1B. The displacement of 3H-1α(OH)D3 with unlabeled 1α,25(OH)2D3 is listed clearly in Table 1 
by the quantitative evaluation of autoradiograms at 2 and 24 hours. 
 In control tissues without radioactivity and in experimental tissues with 0-day autoradiographic 
exposure, silver grain counts were low at background levels and nuclear labeling was absent.   
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Radioassay-HPLC 
 
Plasma and bone levels of 1α,25(OH)2D3 fraction radioactivity were determined at 12, 24, 48, 
72, and 96 hours after administration of 3H-1α(OH)D3 or 3H-1α,25(OH)2D3 (Fig. 2A,B). 
 In plasma, the levels of 1α,25(OH)2D3 fraction radioactivity after administration of 
3H-1α(OH)D3 had maximum concentration (Cmax) at 24 hours, whereas the levels of 
1α,25(OH)2D3 fraction after administration of 3H-1α,25(OH)2D3 had Cmax at 12 hours. The Cmax 
level treated with 1α,25(OH)2D3 was about twice that after 3H-1α(OH)D3 treatment. Between 
48 and 96 hours, the 1α,25(OH)2D3 fraction levels were almost identical in both treatments.  
 In bone, the Cmax of 1α,25(OH)2D3 fraction level after 3H-1α(OH)D3 treatment occurred 
precisely 24 hours after administration, and 3H-1α,25(OH)2D3 treatment occurred at 12 hours 
after administration. The Cmax level 12 hours after 3H-1α,25(OH)2D3 administration was 1.5-fold 
compared with that of 3H-1α(OH)D3; but between 24 and 96 hours after administration, 
1α,25(OH)2D3 fraction levels treated with 3H-1α,25(OH)2D3 were lower than those treated with 
3H-1α(OH)D3. Accordingly, the 1α,25(OH)2D3 fraction in bone treated with 3H-1α,25(OH)2D3 
diminished faster than that treated with 3H-1α(OH)D3. Correspondently, the relative distribution 
ratio [1α,25(OH)2D3 fraction in bone/1α,25(OH)2D3 fraction in plasma] (Fig, 2C) was much 
higher in animals treated with 3H-1α(OH)D3 than in animals treated with 3H-1α,25(OH)2D3, 
especially between 48and 96 hours after administration. 
 The radioassay experiment was repeated twice to confirm the finding of the 3H-1α(OH)D3 
treatment, showing a sustained 3H-1α,25(OH)2D3 fraction in bone when compared with the 
3H-1α,25(OH)2D3 treatment.  
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Discussions 
 
The two methodologies used, although different in dose and specific activity of the radiolabeled   
1α(OH)D3 due to adjustment to the conditions for each procedure, yielded results that were 
mutually supportive. After administration of 3H-1α(OH)D3, uptake of radioactivity, monitored 
by radioassay in bone and by receptor autoradiography in osteoblast nuclei, was relatively slow 
and a sustained accumulation was noted. By comparison, 3H-1α,25(OH)2D3 rapidly 
accumulated in bone and osteoblasts and was soon released from the targets. In receptor 
autoradiography, the source of radioactivity in the nuclei was most likely not to be residues of 
1α(OH)D3 but an active 1α,25(OH)2D3 form because 1α(OH)D3 has a low affinity for vitamin 
D receptor (VDR) (1/900) (Procsal et al. 1975) and the radioactivity in the nuclei was completely 
displaced by unlabeled 1α,25(OH)2D3. 
 After administration of 3H-1α(OH)D3, the sustained presence of radioactivity in target cells 
was probably related to the long plasma T1/2 of 1α(OH)D3 and a continued supply from the 
circulation pool being converted to 3H-1α,25(OH)2D3 (Kains 1977, Seino 1987). The results of 
the bone:plasma ratio in the radioassay and the accumulation of silver grains in osteoblasts 
suggest that the conversion to 3H-1α,25(OH)2D3 from 3H-1α(OH)D3 is likely to occur in bone. 
This assumption is supported further by the presence of 25-hydroxylase in bone (Ichikawa et al. 
1995), in addition to the liver. 
 The present results from both the receptor autoradiography and the radioassay experiments 
provide evidence in support of 1α(OH)D3 as a biologically important vitamin D analogue. The 
data agree with clinical reports on the efficacious treatment of osteoporosis with 1α(OH)D3 
(Orimo et al. 1994). In elderly women with osteoporosis, 1α,25(OH)2D3 bone levels were 
markedly reduced despite normal 1α,25(OH)2D3 blood levels (Lidor et al. 1993). Therefore, 
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elderly persons may need an increase of 1α,25(OH)2D3 in bone for the improvement of 
osteoporosis and fracture repair. Clinical treatment with 1α,25(OH)2D3, however, is limited due 
to side effects caused by hypercalcemia. The use of chemically synthesized 1α(OH)D3 as 
pro-drug has been proposed for the treatment of osteoporosis as a method of choice (Nishii et al. 
1993). This appears to be advantageous because of the sustained local supply in mild 
concentrations of 1α,25(OH)2D3, especially in bone. 
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Fig. 1. 
Autoradiograms of neonatal rat tibia after intravenous injection of 3H-1α(OH) D3 (A,C, E, G, I) 
or 3H-1α,25(OH)2D3 (B,D,F,H,J) showing nuclear concentration of radioactivity in osteoblasts 
of spongiosa at different time intervals. After 3H-1α,25(OH)2D3 injection, nuclear labeling is 
strongest at 2 hours (B) and 8 hours (D), but low or absent at 24 hours (F) and 48 hours (H). In 
contrast, after 3H-1α(OH) D3, nuclear labeling is strongest at 8 hours (C), but weak at 2 hours 
(A), and sustained at low to intermediate levels at 24 hours (E) and 48 hours (G) (arrows 
indicate labeled osteoblasts). In competition experiments, nuclear labeling is eliminated by 
co-injection of 3H-1α(OH) D3 with 10-fold unlabeled 1α,25(OH)2D3 at 2 hours (I) and strongly 
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reduced by co-injection of 3H-1α,25(OH)2D3 with 9-fold unlabeled 1α,25(OH)2D3 at 2 hours (J). 
Three micrometer sections, undecalcified, unfixed, and unembedded, stained with methylene 
blue-basic fuchsin. Exposure time 4 months. Magnification x 527. Bar 20 µm. 
 
 
 
 
 
 
 
 
 
 
 
Table 1. 
Quantitative evaluation of autoradiograms: Mean number of silver grains (SG) over nuclei beforea 
and afterb subtraction of background. BG = background defined as radioactivity per area in 
extranuclear compartments. SG were counted over at least 50 cells for each structure in two rats for 
each condition. Competitionc with 10-fold unlabeled 1α,25(OH)2D3 injected together with 2.0 µg/kg 
of 3H-1α(OH) D3 suppressed or eliminated nuclear concentration of radioactivity. 
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Fig. 2 A,B,C 
Time course of recovered 1α,25(OH)2D3 fraction in plasma (A) and bone (B), and relative 
distribution ratio (C) of recovered 1α,25(OH)2D3 fraction between bone and plasma after oral 
administration of 1α(OH)D3 (-●-) (n=6) and 3H-1α,25(OH)2D3 (-○-) (n=6) in rats. Each point and 
vertical bar represents mean and standard error, respectively. 
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General discussion 
 
It is essential to clarify the in vivo distribution in the target site of new pharmaceutical 
compounds in order to determine its effect. Generally, biochemical approaches using tissue 
homogenate or Macroautoradiography (MacroARG) are used to determine the localization of 
radiolabeled compounds. However, these approaches are insufficient for identifying the cellular 
distribution. I have improved the Microautoradiography technique in order to solve the 
resolution level, and proved that they could compare the amount of distribution among the 
molecules with a similar structure at the cellular level. Microautoradiography was confirmed to 
be a powerful key tool for studying the mode of action of vitamin D derivatives from these 
results, and that it can be applied to a new derivative like Eldecalcitol 
(1α-,25-Dihydroxy-2β-(3-hydroxypropoxy)vitamin D3). In addition to the in vivo study, this 
technique can be applied to organ cultures and in vitro studies. As an example, the amount of 
nuclear distribution of OCT was demonstrated to be more than that of 1α,25(OH)2D3 in the skin 
of psoriasis patients (published in the application for approval of OCT to Ministry of Health, 
Labour, and Welfare).  
 Low molecular weight compounds such as vitamin D derivatives should be labeled with 3H, 
while they will be synthesized in the later stages of drug development. Microautoradiography 
can also possibly be used in compounds labeled with 14C and 125I. Since 125I can be more easily 
incorporated into peptides or proteins such as antibody than 14C and 3H, 125I labeled compounds 
can be used to search for more proof of the concept in earlier stages of drug development.   
In addition to a proof of concept, Microautoradiography can be used to identify unknown 
target cells. A feasibility study, which can be expanded new clinical applications, should be 
conducted for new target cells. From the specific localization of [3H]OCT in the Sertoli cells 
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and the feasibility study with our established animal model for male infertility, it was found that 
ALF had sperm-forming ability, and these results were patented (P2007-215511A). 
 Microautoradiography is expected to be more widely used as a powerful tool for drug 
development in the future.  
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